Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Modine Manufacturing | Moderna | |
|---|---|---|
| Moat rating | none Modine's FY2026 Form 10-K (fiscal year ended 31 March 2026, filed 2026-05-27 as EDGAR accession 0001104659-26-066795; read from the copy on Modine's investor-relations site) describes competitive markets and no structural protection. It says "Most of our products are sold in competitive markets", that "pricing pressures from our customers and pricing actions of our competitors" may "require us to adjust the prices of products to stay competitive", that it experiences "competition from companies in other parts of the world that enjoy economic advantages, such as lower labor costs", and that if it cannot differentiate with technology "we may experience price erosion, lower sales, and lower profit margins." Stored fundamentals from Modine's 10-Ks show gross profit of $365.5 million on $2,212.7 million of revenue in fiscal 2019 and $389.4 million on $2,297.9 million in fiscal 2023; the FY2026 10-K reports gross margin of 24.9 percent for fiscal 2025 and 23.0 percent for fiscal 2026, and the Q1 fiscal 2027 release (2026-07-29) reports 20.8 percent. Customers are concentrated: the ten largest were 49 percent of fiscal 2026 net sales and "one global technology customer" about 11 percent. The strongest counter-evidence is in data centres, where on the Q4 fiscal 2026 call (https://s205.q4cdn.com/270741342/files/doc_financials/2026/q4/Modine_Transcript-Q4-FY26.pdf) the CEO announced an agreement under which "we will guarantee capacity to supply more than 4 billion of data center cooling products during calendar years 2027 through 2029"; but that is a capacity commitment to one existing customer, and the CFO added "Short of an LTA, we don't have multiyear POs. And what this one did is it gave us a really high confidence in a big portion of our two-, three-year outlook." Fast growth in a capacity-short market, without a protected position or a durable margin premium, is not shown to be a moat, so the band is none. | narrow The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion. |
| Moat type | none No moat source is demonstrated in the filings. The 10-K says "our business as a whole is not materially dependent upon any particular patent or license, or any particular group of patents or licenses", although Item 1A says intellectual property "plays an important role in maintaining our competitive position in a number of the markets we serve." Switching costs are the closest candidate: the 10-K says customers ask Modine, "as well as their other primary suppliers", for R&D, design and validation support, and on the Q1 fiscal 2027 call (https://s205.q4cdn.com/270741342/files/doc_financials/2027/q1/Modine_-Transcript-Q1-FY27.pdf) the CEO described a product designed with a specific hyperscaler "in probably the third iteration of the design cycle". But the same 10-K says "Generally, we supply products to our customers on the basis of individual purchase orders received from them", that long-term sales agreements are "typically three to five years in duration", and that its 80/20 pricing strategy "may result in a lower overall win rate for new business", which describes contestable rather than locked-in business. Scale is not claimed as an advantage either: the company competes with "many manufacturers of heat transfer and HVAC&R solutions, some of which are divisions of larger companies". The type is none. | intangibles ip The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power." |
| Leadership | fast follower The 10-K gives no share or rank and names no competitor; it says only "We compete with many manufacturers of heat transfer and HVAC&R solutions, some of which are divisions of larger companies." The independent view is Dell'Oro Group's 3Q 2025 data center physical infrastructure release (2025-12-10, https://www.delloro.com/news/data-center-physical-infrastructure-market-expands-18-percent-y-y-in-3q-2025/), which grouped Modine with rising entrants: "Emerging competitors continued to gain momentum, with Aaon scaling its data center thermal business by an order of magnitude within a few quarters, supported by a very healthy backlog as hyperscalers broaden their supplier base. Modine also strengthened its position, securing notable hyperscale wins that reinforce its rising relevance in large AI campus deployments." On the Q4 fiscal 2026 call the CEO said "From a market demand standpoint, we're in a great competitive position", which is the company's own view. A supplier gaining ground with hyperscalers, described by a tracker as of rising relevance rather than as a leader, is a fast follower. | co leader The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date." |
| Pricing power | weak The filing describes price as something Modine defends rather than sets. Item 1A says "Our sales levels and margins could be adversely affected by pricing pressures from our customers and pricing actions of our competitors", and that its 80/20 pricing strategy, with "clear, strategic profit margin targets for new sales", "may result in a lower overall win rate for new business." Cost recovery is mechanical and lagged: contract adjustments are "limited to the underlying cost of the material", "typically do not include related metals premiums or fabrication costs", and can take "a three-month to one-year lag"; on the Q4 fiscal 2026 call the CFO said "we'll recover tariffs through surcharges and mitigate increasing metals prices with pricing mechanisms in our customer contracts." The fiscal 2025 margin gain in Climate Solutions came "primarily due to favorable sales mix and the favorable impact of commercial pricing settlements"; company gross margin then fell 190 basis points to 23.0 percent in fiscal 2026 and was 20.8 percent in Q1 fiscal 2027 (https://s205.q4cdn.com/270741342/files/doc_financials/2027/q1/Modine-Reports-First-Quarter-Fiscal-2027-Results.pdf). On the Q1 fiscal 2027 call the CEO said the company is "taking decisive pricing actions to offset inflationary cost increases, including materials and tariffs", which is cost recovery, not evidence of a price premium. | weak Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries." |
| Summary | Modine makes thermal management products in two groups, per its FY2026 10-K: Climate Solutions (data centre cooling, heat transfer coils and coatings, refrigeration and power-generation coolers, and HVAC heating and indoor-air-quality products) and Performance Technologies (heat exchangers and cooling modules for vehicles, off-highway equipment and generator sets). Data centre products rose to 35 percent of fiscal 2026 net sales from 25 percent; they include chillers, dry coolers, precision air handling units, CRAC and CRAH units, fan walls, rear-door heat exchangers, coolant distribution units and immersion solutions, sold to hyperscale, colocation, NeoCloud and edge customers. Fiscal 2026 net sales were $3.2 billion, up 23 percent, and on the Q4 fiscal 2026 call the CEO said data centre sales "increased 73% to 1.1 billion" and announced a capacity agreement covering "more than 4 billion of data center cooling products during calendar years 2027 through 2029" with an existing customer. Modine plans to spin off Performance Technologies and combine it with Gentherm, which it expects to close by the end of calendar 2026, leaving a data centre and commercial HVAC company. An independent tracker, Dell'Oro Group (2025-12-10), described Modine among "emerging competitors" that "strengthened its position, securing notable hyperscale wins". The limits are in the 10-K and recent results: most products are sold "in competitive markets" under customer pricing pressure, the ten largest customers were 49 percent of sales, no single patent is material, and gross margin was 23.0 percent in fiscal 2026 and 20.8 percent in Q1 fiscal 2027, when the Data Centers segment's gross margin fell 960 basis points to 20.2 percent on capacity expansion costs and supply shortages. Strong demand and customer co-design are real, but the filings show no protected position or margin premium, so Modine is rated as having no moat. | Moderna's 10-K rests its competitive case on the mRNA platform and the IP wrapped around it: the company states it believes its capabilities "across mRNA technology, drug discovery, development and manufacturing" differentiate it, and reports more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed abroad, 485 pending applications, and granted patents on Spikevax, mNEXSPIKE and mRESVIA projected to expire in 2041 (U.S.) and 2036 (Europe), plus trade secrets and manufacturing know-how it calls substantial. The filing is equally direct about the limits: the principal COVID rival's vaccine "is also based on mRNA technology"; a competitor's European Commission contract keeps Moderna out of many European COVID markets until year-end 2026; RSV sales are "minimal to date" behind Pfizer and GSK; and the risk factors warn that "the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies." What is durable is science and plant rather than commercial position: Moderna bought and operates the Norwood (MTC) campus, completed a Marlborough site purpose-built for intismeran autogene that began shipping patient batches in September 2025, and runs UK, Canada and Australia facilities that were fully licensed in 2025, each government having entered a multi-year commitment to purchase mRNA products from the company. |
| Chain position | Modine supplies facility-level cooling for AI data centres, chiefly chillers and air handling units with a smaller CDU line; on the Q1 fiscal 2027 call the CEO said order growth came from "the three largest customers that we have that are hyperscaler and Neocloud", and the 10-K names one global technology customer at about 11 percent of fiscal 2026 sales. | A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish. |
| Products (share / barrier) |
|
|
| Long-horizon vote | -0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm bearish Editorial prior, not backtested. |